Table 3. Prevalence of antimicrobial resistance in nosocomial and community-acquired invasive isolates of Escherichia coli*.
Antimicrobial agent | Nosocomial |
Community-acquired |
||||
---|---|---|---|---|---|---|
N | R% (n) | N | R% (n) | p | OR (CI 95%) | |
Ampicillin | 3,337 | 61 (2,036) | 3,734 | 54.6 (2,039) | <0.0001 | 1.64 (1.49–1.81) |
Ciprofloxacin | 3,325 | 22.6 (751) | 3,730 | 16.7 (623) | <0.0001 | 1.46 (1.29–1.64) |
Cotrimoxazole | 3,098 | 34.3 (1,063) | 3,484 | 28.2 (982) | <0.0001 | 1.33 (1.20–1.48) |
Gentamicin | 3,328 | 8.8 (293) | 3,721 | 5.2 (193) | <0.0001 | 1.76 (1.46–2.14) |
Cefotaxime | 3,315 | 4.4 (146)† | 3,724 | 1.9 (71)† | <0.0001 | 2.37 (1.76–3.19) |
Multiresistance | 2,414 | 19.3 (466) | 2,586 | 13.1 (339) | <0.0001 | 1.59 (1.36–1.85) |
*R%, percent resistance; OR, odds ratio; CI, confidence interval. †Includes isolates with intermediate susceptibility and resistance.